

Налидиксовая кислота
- английское имяNalidixic acid
- CAS №389-08-2
- CBNumberCB1194283
- ФормулаC12H12N2O3
- мольный вес232.24
- EINECS206-864-7
- номер MDLMFCD00006884
- файл Mol389-08-2.mol
Температура плавления | 227-229 °C (lit.) |
Температура кипения | 374.4°C (rough estimate) |
плотность | 1.2243 (rough estimate) |
показатель преломления | 1.6660 (estimate) |
температура хранения | 2-8°C |
растворимость | chloroform: 20 mg/mL, clear |
форма | Powder |
пка | pKa 6.11± 0.02(Approximate) |
цвет | White to light yellow |
Биологические источники | synthetic |
Растворимость в воде | 0.1 G/L (23 ºC) |
Мерк | 14,6359 |
БРН | 750515 |
Стабильность | Stable. Incompatible with strong oxidizing agents. |
Справочник по базе данных CAS | 389-08-2(CAS DataBase Reference) |
FDA UNII | 3B91HWA56M |
Предложение 65 Список | Nalidixic Acid |
Код УВД | J01MB02 |
Система регистрации веществ EPA | Nalidixic acid (389-08-2) |
UNSPSC Code | 41116107 |
NACRES | NA.77 |
Коды опасности | Xn | |||||||||
Заявления о рисках | 63-42/43-40-20/21/22-22 | |||||||||
Заявления о безопасности | 22-36/37-45-24-36 | |||||||||
WGK Германия | 2 | |||||||||
RTECS | QN2885000 | |||||||||
F | 8-10-23 | |||||||||
кода HS | 29339190 | |||||||||
Банк данных об опасных веществах | 389-08-2(Hazardous Substances Data) | |||||||||
Токсичность | LD50 in mice (mg/kg): 3300 orally; 500 s.c.; 176 i.v. (Lesher, 1962) | |||||||||
NFPA 704: |
|
рисовальное письмо(GHS)
-
рисовальное письмо(GHS)
-
сигнальный язык
предупреждение
-
вредная бумага
H302:Вредно при проглатывании.
H351:Предполагается, что данное вещество вызывает раковые заболевания.
-
оператор предупредительных мер
P202:Перед использованием ознакомиться с инструкциями по технике безопасности.
P264:После работы тщательно вымыть кожу.
P270:При использовании продукции не курить, не пить, не принимать пищу.
P280:Использовать перчатки/ средства защиты глаз/ лица.
P301+P312:ПРИ ПРОГЛАТЫВАНИИ: Обратиться за медицинской помощью при плохом самочувствии.
P308+P313:ПРИ подозрении на возможность воздействия обратиться за медицинской помощью.
Налидиксовая кислота химические свойства, назначение, производство
Химические свойства
Crystalline PowderИспользование
Nalidixic acid(NegGram) is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase. Evidence exists that the active metabolite, hydroxynalidixic acid, binds stronОпределение
ChEBI: A monocarboxylic acid comprising 1,8-naphthyridin-4-one substituted by carboxylic acid, ethyl and methyl groups at positions 3, 1, and 7, respectively.Антимикробная активность
It displays good activity in vitro against a wide range of Enterobacteriaceae.Общее описание
Cream-colored powder.Реакции воздуха и воды
Insoluble in water.Угроза здоровью
SYMPTOMS: Ingestion of Nalidixic acid may cause nausea, vomiting, abdominal pain, allergic reactions and possible liver damage.Пожароопасность
Flash point data for Nalidixic acid are not available, but Nalidixic acid is probably combustible.Фармацевтические приложения
A 1,8 naphthyridone derivative available for oral administration.Фармакокине?тика
Oral absorption: >90%Cmax 1 g oral: c. 25 mg/L
Plasma half-life:c.1.5h
Volume of distribution :0.4 L/kg
Plasma protein binding: 93%
The plasma concentrations achieved after oral administration vary widely. In infants with acute shigellosis, absorption is much impaired by diarrhea. Administration with an alkaline compound leads to higher plasma concentrations, partly as the result of enhanced solubility (nalidixic acid is much more soluble at higher pH) and absorption and partly because of reduced tubular reabsorption.
It is rapidly metabolized, principally to the hydroxy acid, which is bacteriologically active, and glucuronide conjugates, which are not. The entire administered dose appears in the urine over a 24 h period. Elimination is reduced by probenecid. In the presence of renal impairment there is little accumulation of the active compound because it continues to be metabolized. However, elimination of metabolites is progressively delayed as renal function declines. About 4% of a dose appears in the feces.
Клиническое использование
1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid (NegGram) occurs as a pale buff crystalline powder that is sparingly soluble in water and ether but solublein most polar organic solvents.Nalidixic acid is useful in the treatment of urinary tractinfections in which Gram-negative bacteria predominate.The activity against indole-positive Proteus spp. is particularlynoteworthy, and nalidixic acid and its congeners representimportant alternatives for the treatment of urinary tractinfections caused by strains of these bacteria resistant toother agents. Nalidixic acid is rapidly absorbed, extensivelymetabolized, and rapidly excreted after oral administration.The 7-hydroxymethyl metabolite is significantly more activethan the parent compound. Further metabolism of theactive metabolite to inactive glucuronide and 7-carboxylicacid metabolites also occurs. Nalidixic acid possesses at1/2elim of 6 to 7 hours. It is eliminated, in part, unchanged inthe urine and 80% as metabolites.Побочные эффекты
Adverse reactions are generally those common to all quinolones: gastrointestinal tract and CNS disturbances and skin rashes, including eruptions related to photosensitivity. About half of the reported CNS reactions involve visual disturbances, hallucinations or disordered sensory perception. Severe excitatory states, including acute psychoses and convulsions, are usually observed in patients receiving high dosages. The drug should be avoided in patients with psychiatric disorders or epilepsy.Acute intracranial hypertension has been observed in children, some of whom have also manifested cranial nerve palsies. Hemorrhage has occurred in patients who were also receiving warfarin, presumably due to displacement of the anticoagulant from its protein binding sites by the nalidixic acid. Hemolytic anemia has been described several times in infants with or without glucose-6-phosphate dehydrogenase deficiency; in adults, death has occurred from autoimmune hemolytic anemia. Arthralgia and severe metabolic acidosis have rarely been reported.
Профиль безопасности
Poison by intravenous and intraperitoneal routes. Moderately toxic by ingestion and subcutaneous routes. An experimental teratogen. Human systemic effects: convulsions, hyperglycemia, sweating, and blood changes in children. Experimental reproductive effects.Questionable carcinogen with experimental carcinogenic and tumorigenic data. Human mutation data reported. Used as an antibacterial agent and urinary tract antiseptic. When heated to decomposition it emits toxic fumes of NOx.Методы очистки
Nalidixic acid crystallises from H2O or EtOH as a pale buff powder. It is soluble at 23o in CHCl3 (3.5%), toluene (0.16%), MeOH (0.13%), EtOH (0.09%), H2O (0.01%) and Et2O (0.01%). It inhibits nucleic acid and protein synthesis in yeast. [Lesher et al. J Med & Pharm Chem 5 1063 1962.]Налидиксовая кислота запасные части и сырье
сырьё
1of3
запасной предмет
Налидиксовая кислота поставщик
поставщик | телефон | страна | номенклатура продукции | благоприятные условия |
---|---|---|---|---|
+86-029-81138252 +86-18789408387 |
China | 3889 | 58 | |
+8617531153977 | China | 5855 | 58 | |
+86-(0)57185586718 +86-13336195806 |
China | 29792 | 60 | |
+86-371-66670886 | China | 19902 | 58 | |
+86-0371-55170693 +86-19937530512 |
China | 21632 | 55 | |
+86-0371-86658258 +8613203830695 |
China | 29871 | 58 | |
+86-023-6139-8061 +86-86-13650506873 |
China | 39894 | 58 | |
+8618523575427 | China | 49732 | 58 | |
+1-781-999-5354 +1-00000000000 |
United States | 32161 | 58 | |
+8613367258412 | China | 10319 | 58 |